(19)
(11) EP 1 945 631 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.01.2013 Bulletin 2013/01

(45) Mention of the grant of the patent:
08.08.2012 Bulletin 2012/32

(21) Application number: 06794902.4

(22) Date of filing: 26.10.2006
(51) International Patent Classification (IPC): 
C07D 403/14(2006.01)
A61P 35/00(2006.01)
 A61K 31/506(2006.01)
(86) International application number:
PCT/GB2006/003978
(87) International publication number:
WO 2007/049041 (03.05.2007 Gazette 2007/18)

(54)

4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER

4-(3-AMINOPYRAZOL)PYRIMIDINDERIVATE ZUR VERWENDUNG ALS TYROSINKINASEINHIBITOREN BEI DER BEHANDLUNG VON KREBS

DERIVES 4-(3-AMINOPYRAZOLE)PYRIMIDINE ET LEUR UTILISATION EN TANT QU' INHIBITEURS DE TYROSINE KINASES DANS LE CADRE D UN TRAITEMENT ANTICANCEREUX

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 28.10.2005 US 731299 P
24.05.2006 US 803061 P

(43) Date of publication of application:
23.07.2008 Bulletin 2008/30

(60) Divisional application:
11177767.8 / 2388259

(73) Proprietor: AstraZeneca AB
151 85 Södertälje (SE)

(72) Inventors:
  • FENG, Xiaomei
    Waltham, Massachusetts 02451 (US)
  • GUAN, Huiping
    Waltham, Massachusetts 02451 (US)
  • KAN, Ying
    Shanghai 201203 (CN)
  • IOANNIDIS, Stephanos
    Waltham, Massachusetts 02451 (US)
  • PENG, Bo
    Waltham, Massachusetts 02451 (US)
  • SU, Mei
    Waltham, Massachusetts 02451 (US)
  • WANG, Bin
    Longmont, Colorado 80501 (US)
  • WANG, Tao
    Waltham, Massachusetts 02451 (US)
  • ZHANG, Hai-Jun
    Waltham, Massachusetts 02451 (US)


(56) References cited: : 
WO-A-2005/049033
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).